Key result
Guanxinning tablets plus aspirin reduces cardiovascular events ~21% versus aspirin alone post-PCI.
Why the study?
Prolonged dual antiplatelet therapy after PCI reduces thrombotic risk but increases bleeding, creating a therapeutic dilemma that GXNT may address.
Does Guanxinning tablets combined with aspirin reduce cardiovascular events in patients with coronary heart disease who have completed at least 12 months of DAPT following PCI?
RCT (n=3,586)
Open-label
cluster-randomized
Yes
Does Guanxinning tablets combined with aspirin reduce cardiovascular events in patients with coronary heart disease who have completed at least 12 months of DAPT following PCI?
In patients who completed 12 months of DAPT post-PCI, adding Guanxinning tablets to aspirin reduced adverse cardiovascular events without increasing major bleeding.
Answers are grounded in this paper and cite their sources.
Adding GXNT to aspirin reduces post-PCI events without excess bleeding; extends adjunctive options during DAPT-to-monotherapy transition.
BACKGROUND: Prolonged dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) lowers thrombotic risk but increases bleeding, creating a therapeutic dilemma. Guanxinning tablets (GXNT), a traditional Chinese medicine with antithrombotic and cardioprotective effects, may offer an alternative strategy. PURPOSE: To evaluate whether GXNT combined with aspirin reduces cardiovascular events without increasing bleeding in patients transitioning from DAPT to aspirin monotherapy after PCI. STUDY DESIGN: An open-label, cluster-randomized controlled trial conducted in 63 tertiary hospitals in China between March 2017 and December 2018. METHODS: A total of 3586 patients with coronary heart disease (CHD) who had completed at least 12 months of DAPT following PCI were enrolled. Hospitals and participants were randomized in a 2:1 ratio to receive GXNT plus aspirin or aspirin alone for 12 months, followed by 12 months of additional follow-up. The primary endpoint was a composite of cardiovascular death, non-fatal myocardial infarction, stent thrombosis, revascularization, ischemic stroke, and rehospitalization for unstable angina. Outcome assessors and data analysts were blinded to treatment allocation. The intention-to-treat analysis principle was adopted, and ICC were accounted for in the statistical analysis. RESULTS: Of the participants, 2389 received GXNT plus aspirin and 1197 received aspirin alone. After a median follow-up of 23 months, GXNT significantly reduced the primary outcome (11.0 % vs. 13.2 %; adjusted hazard ratio [HR] 0.79, 95 % confidence interval [CI] 0.63-0.98). Rates of revascularization (3.8 % vs 4.7 %) and rehospitalization for unstable angina (7.0 % vs 9.7 %) were also lower in the GXNT group. Major bleeding events were rare and similar across groups. CONCLUSION: GXNT combined with aspirin reduced adverse cardiovascular events after PCI without increasing bleeding, supporting its potential as an alternative to prolonged DAPT.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2025) conducted an RCT in coronary heart disease (CHD) (n=3,586). Guanxinning tablets plus aspirin vs. aspirin alone was evaluated on composite of cardiovascular death, non-fatal myocardial infarction, stent thrombosis, revascularization, ischemic stroke, and rehospitalization for unstable angina (HR 0.79, 95% CI 0.63-0.98). Guanxinning tablets plus aspirin reduced the composite of cardiovascular events compared to aspirin alone after PCI (11.0% vs. 13.2%; HR 0.79; 95% CI 0.63-0.98).
Synapse has enriched 10 related papers. Consider them for comparative context: